The global cell and gene therapy biomanufacturing CDMO market - focused on AAV was valued at $231.3 million in 2022 and is anticipated to reach $2,566.6 million by 2033, witnessing a CAGR of 24.61% during the forecast period 2023-2033.
The global biomanufacturing viral detection and quantification market was valued at $474.3 million in 2022 and is anticipated to reach $1,149.7 million by 2032, witnessing a CAGR of 9.37% during the forecast period 2023-2032.
The global constrained peptide drugs market is expected to reach $17.38 billion in 2040 from $0.06 billion in 2024, growing at a CAGR of 38.94% during the forecast period 2025-2040.
The global gene editing technologies market was valued at $1.81 billion in 2022 and is anticipated to reach $16.37 billion by 2032, witnessing a CAGR of 27.50% during the forecast period 2023-2032.
The global cell-based assay market is expected to reach $38.23 billion in 2032 from $17.20 billion in 2022, at a CAGR of 8.44% during the forecast period 2023-2032.
Need reports on an on-going basis? Do consider our annual subscription
The global nucleic acid therapeutics CDMO market was valued at $3.88 billion in 2022 and is expected to reach $14.19 billion by 2033, growing at a CAGR of 12.55% during the forecast period 2023-2033.
The global cell and gene therapy biomanufacturing market was valued at $12.31 billion in 2022 and is anticipated to reach $29.76 billion by 2031, witnessing a CAGR of 10.31% during the forecast period 2022-2031.
The report focuses solely on the extensive stage small cell lung cancer treatment, which includes approved products as well as products under clinical development.
The global phosphoramidite market is projected to reach $2,062.9 million by 2032 from $900.3 million in 2021, at a CAGR of 7.78% during the forecast period 2022-2032.
In 2021, the global 3D protein structure analysis market was valued at $1,017.2 million, and it is expected to reach $2,676.6 million by 2032, growing at a CAGR of 9.32% during the forecast period 2022-2032.
The global market for serum-free media was valued at $1,022.4 million in 2021 and is expected to reach $3,920.5 million by 2032, registering a CAGR of 12.73% during the forecast period 2022-2032.
The report provides an exhaustive list of pipeline products which are currently in the development along with their developmental details in various indications.
The global FLT3 inhibitors market is expected to reach $2,061.3 million in 2032 from $400.9 million in 2021 at a CAGR of 14.88% during the forecast period 2022-2032.
The global pharmaceutical aseptic transfer market is projected to reach $2,551.5 million by 2031 from $855.2 million in 2021 at a CAGR of 9.61% during the forecast period 2022-2031.
The global narcolepsy therapeutics market is projected to reach $4,912.3 million by 2032 from $915.2 million in 2021 at a CAGR of 15.93% during the forecast period 2022-2032.
The global ligase market is projected to reach $651.4 million by 2032 from $371.2 million in 2021, at a CAGR of 5.29% during the forecast period 2022-2032.
In 2021, the global microbiome therapeutics market valued $306.3 million, and it is estimated to reach $3,204 million by 2032, registering a CAGR of 24.95% during the forecast period 2022-2032.
The global NK cell therapeutics market is expected to reach $5,676.1 million in 2032 from $297.2 million in 2024 at a CAGR of 44.59% during the forecast period 2024-2032.
In 2021, the global axial spondyloarthritis market was valued at $1,873.8, which is expected to reach $7,937.8 million in 2032 by witnessing a growing CAGR of 13.44% during the forecast period, 2022-2032.
The global blood and plasma components market is projected to reach $66.47 billion in 2031 from $39.58 billion in 2020, witnessing a CAGR of 4.90% during the forecast period 2021-2031.
The global radioligand therapy market is projected to reach $16,658.4 million by 2031, growing from $9,754.9 million in 2020, at a CAGR of 4.67% during the forecast period 2021-2031.
In 2020, the global hematological malignancies emerging therapeutics market was valued at $8,444.8 million, which is expected to reach $43,966.8 million in 2031.
The global aseptic pharma processing market was valued to be $10,633.3 million in 2020 and is expected to reach $24,364.0 million by 2031, witnessing a CAGR of 7.90% during the forecast period 2021-2031.
The global NIPT market was valued at $2.52 billion in 2020 and is expected to reach $12.61 billion by 2031, registering a CAGR of 15.79% during the forecast period 2021-2031.
The global viral and non-viral vector manufacturing market was valued at $1.50 billion in 2020 and is expected to reach $27.03 billion by 2031, witnessing a CAGR of 18.54% during the forecast period 2021-2031.
The global CRISPR gene editing market was valued at $1,088.6 million in 2020 and is expected to reach $18,856.6 million by 2031, witnessing a CAGR of 29.60% during the forecast period 2021-2031.
The global next-generation biomanufacturing market is expected to grow at a CAGR of 14.85% during the forecast period 2021-2031 and is expected to reach a value of $85,201.2 million in 2031.
The global constrained peptide drugs market is anticipated to be valued at $60.1 million in 2023 and is expected to reach $10,367.2 million by 2031, witnessing a CAGR of 90.37% during the forecast period 2023-2031.
The global imaging CRO market is expected to grow at a CAGR of 7.25% during the forecast period 2021-2031 and is expected to reach a value of $9,603.0 million in 2031.
The global nucleic acid therapeutics CDMO market was valued at $1,546.4 million in FY2020 and is estimated to reach $4,463.7 million by 2030.
The global market for aseptic pharma processing equipment is predicted to grow at a CAGR of 7.29% over the forecast period 2021-2030.
The global market for in-vitro fertilization is predicted to grow at a CAGR of 9.37% over the forecast period 2020-2030.
The global SERD therapeutics market was valued at $1000.2 million in 2019 and is expected to reach $4085.0 million by 2030.
The global cell and gene therapy drug delivery devices market was valued at $55.75 thousand in 2019, and is expected to reach $375.13 thousand by 2030.
The global industrial microbiology market was valued to be $5,604.2 million in 2019 and is expected to reach $13,181.2 million by 2030.
The global market for microbiome therapeutics is predicted to grow at a CAGR of 25.64% over the forecast period of 2020-2030.
The global bioengineered skin substitutes market was valued at $1.31 billion in 2019 and is expected to reach $4.33 billion by 2030.
The global market for CAR T-cell therapy is predicted to grow at a CAGR of 44.79% over the forecast period 2020-2030.
The global market for autoimmune disorder drug delivery devices is predicted to grow at a CAGR of 15.25% over the forecast period of 2020-2030.
The global market for neurodegenerative disorder therapeutics is predicted to grow at a CAGR of 7.21% over the forecast period of 2020-2030.
By volume, global NIPT market was 3.14 million units in 2019 and is expected to reach 23.58 million units by 2030.
The global market for PD-1/PD-L1 immunotherapy is predicted to grow at a CAGR of 10.72% over the forecast period of 2020-2030.
The global market for IVD is predicted to grow at a CAGR of 5.06% over the forecast period of 2020-2030.
The global market for infectious disease biomarker testing market is predicted to grow at a CAGR of 14.48% during the forecast period of 2020-2030.
In 2019, the market size of the global tumor genomics market was valued at $8,131.0 million, and is expected to reach $16,287.2 million in 2028, registering a CAGR of 8.09% during the forecast period between 2020-2028.
Global Viral Vector and Plasmid Manufacturing Market to Reach $5.86 Billion by 2030.
The Global Bioremediation Market report by BIS Research projects the market to grow at a significant CAGR of 7.72% during the forecast period from 2019 to 2028.
The Global Next-Generation Biomanufacturing Market Report by BIS Research projects the market to grow at a significant CAGR of 10% during the forecast period, 2019-2029.
The global hematology testing market was valued to be $4.54 billion in 2018 and is anticipated to witness an impressive single-digit growth rate, to reach $XX billion by 2029.
The North America cannabis industry analysis by BIS Research highlights that the market was valued at $13.21 billion in 2018 and is expected to reach $36.7 billion in 2025.
The Asia-Pacific IVF market is valued at $6.99 billion in 2018, and is expected to witness a CAGR of 10.13% during the forecast period between 2019 and 2029.
The global sports medicine market was estimated to be $5.99 billion in 2018 and is expected to be $9.25 billion by 2026. It is expected to grow at a CAGR of 5.64% from 2019 to 2026.
The global human microbiome modulators market has been witnessing a steady annual growth rate of approximately 6.08% in past three years (2015-2017), and the market is expected to continue to grow with a double digit CAGR of 16.29% during the forecast period, 2018-2023.
The global vaccine market is anticipated to reach $103.57 billion by 2028, witnessing a CAGR of 11.02% in the forecast period 2018-2028.
The global nanopharmaceutical drug market is valued $40.37 billion in 2017 and is expected to reach $79.29 billion by 2026.
The global enzymes market was valued $6.57 billion in 2017 and is anticipated to reach $10.63 billion by 2025.
The global biosensors market was valued at $1.46 billion in 2017 and is anticipated to reach $3.90 billion in 2027, registering a CAGR of 10.34% in the forecast period 2018-2027..
The global CRISPR technology market is expected to reach $10.55 billion by 2027.
The global women’s health market was estimated at $30.88 billion in 2016 and is estimated to grow over $42.12 billion by 2023. The rising geriatric population among women leading to higher incidence rate of menopause and related diseases is the major factor driving the growth of the market.
The pharmaceuticals and biotechnology as well as food and beverages industry are the largest end users in industrial microbiology market due to increasing drug development, growing demand of pathogen testing in food products and increase in significance of industrial food and safety.
The global biologics drug discovery market was estimated to be $8.9 billion in 2016 and is estimated to grow over $22.7 billion by 2025. Introduction of targeted therapies coupled with rising adoption of patient centric personalized medicine is expected to fuel the demand for biologics drugs in the future.
The global biologics market generated a revenue of $238.8 billion in 2016. Introduction of targeted therapies coupled with rising adoption of patient centric personalized medicine is expected to fuel the demand for biologics drugs in the future.
The global GERD drugs market has a low growth potential in future and will account to $5.38 billion by 2023. Due to side effects of drugs on long term use, patients who fail to respond to medication & the availability of new technology, the device market is set to grow in future.
IVD is expected to increase to $76 billion by 2023 and increase its influence over healthcare spending globally. The category’s rate of growth is accelerating due to a number of key macro forces, such as demand from emerging economies, aging population, evolving clinician attitudes, and a much needed push towards theranostics and personalized medicine.
The global IVF market includes pre-treatment drugs and lab equipment, instrument & reagents. In this report the pre-treatment drugs market is not taken into consideration. The global market is expected to grow over $26.08 billion by 2022. IVF Market can be further divided into various segments and sub-segments.
The global constrained peptide drugs market is anticipated to be valued at $60.1 million in 2023 and is expected to reach $10,367.2 million by 2031, witnessing a CAGR of 90.37% during the forecast period 2023-2031.
The global nucleic acid therapeutics CDMO market was valued at $1,546.4 million in FY2020 and is estimated to reach $4,463.7 million by 2030.
The global market for microbiome therapeutics is predicted to grow at a CAGR of 25.64% over the forecast period of 2020-2030.
By volume, global NIPT market was 3.14 million units in 2019 and is expected to reach 23.58 million units by 2030.
The Global Next-Generation Biomanufacturing Market Report by BIS Research projects the market to grow at a significant CAGR of 10% during the forecast period, 2019-2029.
A PHP Error was encountered
Severity: Warning
Message: Invalid argument supplied for foreach()
Filename: web/catdetailsnew.php
Line Number: 695
Life Sciences & Biopharma
The life science and biopharmaceuticals market focus on disruptive innovations in the fields such as therapeutics, drug delivery devices, drug manufacturing, cell and gene therapies, and other new-age treatment therapies.
While these innovations are fuelling the results for the healthcare industry, the demand for newer, more effective therapies and medicine is also growing. Because of this, the challenges for the life sciences and biopharma companies are becoming more demanding; however, the industry is expecting tremendous growth in the coming years.
The life sciences sector is at an inflection point. To prepare for the future and remain relevant in the ever-evolving business landscape, BIS Research offers syndicated and customized solutions to create value and new metrics to optimize business across the biopharmaceuticals and biotechnologies industry. BIS Research also provides leaders with key questions and actions to consider in the year ahead.
BIS Research’s studies in the life science and biopharmaceuticals market help track the rapid growth of gene therapy, cell therapy, biologics, and vaccines that are driving the market, as well as improve visibility on emerging trends, regulations, and competitor landscape that promises to address key challenges in the healthcare industry.
Further, the reports have certain segments of the life science and biopharma industry that are expected to quadruple their current sizes by the end of this decade. This expectation of fantastic growth has turned this challenging field of business into an ocean of lucrative opportunities for business leaders that have the right vision. The life sciences segment encompasses products and technologies in the fields of biotechnology, pharmaceuticals, biomedical technologies, and laboratory technologies that are used in the various stages of research, development, technology transfer, and commercialization of healthcare solutions.
Hundreds of businesses in this industry have trusted BIS Research’s insight reports to make important decisions and grow in the market. From a regional perspective, we are witnessing the early adoption of deep technologies in the life science and biopharmaceutical market in the countries such as the U.S., the U.K., China, Germany, Japan, Canada, France, South Korea, and others.
Our customer base expands across several sections, including small enterprises, medium-scale operations, Fortune 50+ companies, as well as government organizations, venture capitalists, and deemed universities.
BIS Research’s Life Science and Biopharmaceuticals segments offer intelligence reports with solutions aimed at helping healthcare businesses improve operational efficiency and patient outcomes and reduce costs. With the help of its exhaustive research projects, the company has developed a comprehensive and unique country-level database of healthcare infrastructure. BIS Research is keeping a close watch on the latest life science and biopharmaceutical industry developments. In case you do not find a report of your choice in the above-mentioned list, please feel free to contact us for customizing a report for you.
I would like to extend our appreciation for your support in finalizing the report according to our precise needs and prerequisites. I am also impressed by the timely completion of all aspects of dealing with us as your esteemed client. I look forward to continue our professional relations in the future.
Manager-Strategy & Business DevelopmentICL Industrial Products
“I found the content quite interesting and insightful. It has provided us with some important information”
Strategic Insights COE ManagerJapan Tobacco International
I appreciate the extra effort that team BIS took to cater to our specific requirements, moreover, their response time and adaptability is at par with my expectation.
CEO & ChairmanTEKNA Plasma Systems
“BIS research has been a great support to our strategic investigation in the field of thermoplastic composite. BIS did manage to bring together a clear picture on a global level, supported by examples and references and they delivered an accurate evaluation of the current market size and potential in the coming years in line with our expectations. I warmly recommend them.”
VPFuture Business and Innovation